Basic information about inhibitors

IPAD-DB ID	C00730
Name	Engeletin
Category	Natural compounds
2D Structure
3D Structure
Molecular Formula	C 2 1 H 2 2 O 1 0
Molecular Weight	434.4g/mol
IUPAC Name	(2R, 3R)-5, 7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S, 3R, 4R, 5R, 6S)-3, 4, 5-trihydroxy-6-methyloxan-2-yl]oxy-2, 3-dihydrochromen-4-one
InChI	InChI=1S/C21H22O10/c1-8-15(25)17(27)18(28)21(29-8)31-20-16(26)14-12(24)6-11(23)7-13(14)30-19(20)9-2-4-10(22)5-3-9/h2-8, 15, 17-25, 27-28H, 1H3/t8-, 15-, 17+, 18+, 19+, 20-, 21-/m0/s1
InChIKey	VQUPQWGKORWZII-WDPYGAQVSA-N
Canonical SMILES	CC1C(C(C(C(O1)OC2C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)O
PubChem CID	6453452
DrugBank Accession Number	-
CAS Registry Number	572-31-6

Biological activity data

Ki	-
EC50	-
IC50	-
Inhibition	-
Toxicity	-
ROS(reactive oxygen species)	decreased production of reactive oxygen species (ROS)
Metal Chelating	-
BBB(blood-brain barrier)	-
Target Protein	Aβ1-42
Effects	(1) Treatment with engeletin suppressed Aβ1–42-induced viability reduction and lactate dehydrogenase (LDH) release in BV-2 cells, (2)Aβ1–42-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression were inhibited by engeletin treatment, (3)engeletin inhibited Aβ1–42-induced production and mRNA levels of tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), and interleukin 6 (IL-6), (4)Engeletin enhanced Aβ1–42-induced activation of Kelch-like ECH-associated protein 1 (Keap1)/nuclear transcription factor E2-related factor 2 (Nrf2) signaling pathway in BV-2 cells,
Research Models	BV-2 cells
Main Source	From the leaves of Engelhardia roxburghiana
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME)	434.39
Hac(Computed by SwissADME)	31
Volume(Computed by ADMETlab 2.0)	406.993
Density(Computed by ADMETlab 2.0)	1.067
nRing(Computed by ADMETlab 2.0)	4
MaxRing(Computed by ADMETlab 2.0)	10
nHet(Computed by ADMETlab 2.0)	10
fChar(Computed by ADMETlab 2.0)	0
nRig(Computed by ADMETlab 2.0)	24
Flexibility(Computed by ADMETlab 2.0)	0.125
Stero Centers(Computed by ADMETlab 2.0)	7
LogS(Computed by ADMETlab 2.0)	-3.908
LogD(Computed by ADMETlab 2.0)	1.411

ADMET properties

logP(Computed by ADMETlab 2.0)	0.33
TPSA(Computed by SwissADME)	166.14 Ų
Hbond Acceptor(Computed by SwissADME)	10
Hbond Donor(Computed by SwissADME)	6
Rotatable Bonds(Computed by SwissADME)	3

Pharmacokinetics

GI Absorption(Computed by SwissADME)	Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME)	No
P-gp Substrate(Computed by SwissADME)	Yes
CYP1A2 Inhibitor(Computed by SwissADME)	No
CYP2C19 Inhibitor(Computed by SwissADME)	No
CYP2C9 Inhibitor(Computed by SwissADME)	No
CYP2D6 Inhibitor(Computed by SwissADME)	No
CYP3A4 Inhibitor(Computed by SwissADME)	No
log Kp(Skin Permeation)(Computed by SwissADME)	-8.42 cm/s

Druglikeness

Lipinski(Computed by SwissADME)	Yes, 1 violation: NHorOH>5
Ghose(Computed by SwissADME)	Yes
Veber(Computed by SwissADME)	No, 1 violation: TPSA>140
Egan(Computed by SwissADME)	No, 1 violation: TPSA>131.6
Muegge(Computed by SwissADME)	No, 2 violations: TPSA>150, H-don>5
Bioavailability Score(Computed by SwissADME)	0.55